Index- P/E- EPS (ttm)-0.00 Insider Own6.00% Shs Outstand33.47M Perf Week-1.11%
Market Cap249.00M Forward P/E- EPS next Y-0.06 Insider Trans0.00% Shs Float12.42M Perf Month2.16%
Income0.30M PEG- EPS next Q-0.03 Inst Own29.30% Short Float0.35% Perf Quarter-1.80%
Sales49.50M P/S5.03 EPS this Y136.90% Inst Trans-2.17% Short Ratio0.76 Perf Half Y27.93%
Book/sh1.61 P/B4.41 EPS next Y41.70% ROA0.40% Target Price11.33 Perf Year5.19%
Cash/sh1.40 P/C5.06 EPS next 5Y3.00% ROE0.60% 52W Range5.00 - 7.88 Perf YTD18.53%
Dividend- P/FCF- EPS past 5Y-30.30% ROI-2.80% 52W High-9.90% Beta1.30
Dividend %- Quick Ratio3.70 Sales past 5Y4.40% Gross Margin42.40% 52W Low42.00% ATR0.30
Employees227 Current Ratio4.10 Sales Q/Q26.20% Oper. Margin-4.10% RSI (14)53.43 Volatility3.39% 4.45%
OptionableYes Debt/Eq0.11 EPS Q/Q-58.80% Profit Margin0.60% Rel Volume0.81 Prev Close7.14
ShortableYes LT Debt/Eq0.10 EarningsMar 30 AMC Payout0.00% Avg Volume57.22K Price7.10
Recom2.00 SMA204.53% SMA500.49% SMA2009.77% Volume46,200 Change-0.56%
Apr-28-21Initiated Piper Sandler Overweight $13
Apr-15-20Initiated B. Riley FBR Buy $5.50
Jul-28-14Downgrade Northland Capital Outperform → Market Perform $6 → $3.50
Jun-16-14Initiated H.C. Wainwright Buy $6
Mar-05-13Initiated Northland Capital Outperform $6
Nov-18-10Reiterated Morgan Joseph Buy $3 → $5.25
Aug-20-09Reiterated Roth Capital Hold $2.50 → $5
Nov-24-08Reiterated Roth Capital Hold $2.50
Mar-26-08Reiterated Roth Capital Hold $6 → $4.50
Nov-09-07Reiterated Roth Capital Hold $7 → $6
Mar-16-07Reiterated Roth Capital Hold $8.50 → $7
Jan-24-07Reiterated Roth Capital Hold $6.50 → $8.50
May-17-22 04:35PM  
May-10-22 08:30AM  
May-05-22 08:30AM  
Apr-12-22 08:00AM  
Mar-30-22 04:35PM  
Mar-21-22 08:00AM  
Mar-17-22 08:20AM  
Feb-09-22 05:19AM  
Feb-01-22 08:00AM  
Jan-13-22 08:00AM  
Jan-05-22 08:00AM  
Jan-04-22 05:32AM  
Nov-29-21 09:30AM  
Nov-20-21 07:29AM  
Nov-17-21 04:35PM  
Nov-10-21 08:00AM  
Sep-29-21 03:26PM  
Sep-28-21 08:00AM  
Sep-14-21 08:00AM  
Sep-07-21 04:35PM  
Aug-25-21 04:35PM  
Aug-11-21 03:52AM  
Aug-04-21 08:00AM  
Jul-20-21 08:00AM  
Jun-15-21 08:00AM  
May-13-21 01:43AM  
May-12-21 06:45AM  
May-11-21 04:30PM  
May-04-21 08:00AM  
Apr-23-21 06:43AM  
Apr-22-21 04:01PM  
Apr-03-21 04:19AM  
Mar-31-21 06:30AM  
Mar-30-21 04:35PM  
Mar-29-21 10:05AM  
Mar-23-21 08:00AM  
Mar-03-21 08:00AM  
Jan-24-21 01:59AM  
Jan-20-21 08:00AM  
Jan-19-21 08:00AM  
Jan-14-21 08:00AM  
Jan-11-21 08:32AM  
Jan-06-21 08:00AM  
Jan-05-21 08:00AM  
Dec-30-20 08:00AM  
Dec-09-20 08:00AM  
Nov-27-20 10:08AM  
Nov-19-20 06:45AM  
Nov-18-20 05:00PM  
Nov-17-20 10:12AM  
Nov-10-20 08:46AM  
Nov-09-20 08:50AM  
Sep-29-20 08:33AM  
Sep-15-20 08:00AM  
Sep-10-20 07:22AM  
Sep-09-20 08:00AM  
Sep-03-20 08:00AM  
Aug-26-20 04:35PM  
Aug-25-20 08:00AM  
Aug-19-20 08:00AM  
Aug-18-20 08:00AM  
Aug-03-20 12:17PM  
Jul-20-20 09:19AM  
Jul-15-20 08:06AM  
Jul-07-20 11:02PM  
Jun-30-20 04:41PM  
May-28-20 08:35AM  
May-27-20 01:36PM  
May-13-20 04:35PM  
May-12-20 04:35PM  
May-06-20 08:30AM  
May-04-20 08:22AM  
Apr-04-20 08:50AM  
Mar-31-20 06:30AM  
Mar-30-20 04:35PM  
Mar-24-20 08:35AM  
Mar-17-20 08:35AM  
Feb-18-20 08:25AM  
Jan-29-20 08:30AM  
Jan-09-20 08:30AM  
Dec-31-19 11:46AM  
Dec-20-19 10:45AM  
Dec-19-19 08:30AM  
Nov-26-19 08:29AM  
Nov-18-19 09:00AM  
Nov-14-19 06:01AM  
Nov-13-19 04:32PM  
Oct-30-19 08:00AM  
Oct-24-19 08:00AM  
Sep-30-19 07:33AM  
Sep-26-19 08:31AM  
Sep-20-19 10:40AM  
Sep-06-19 10:07AM  
EDAP TMS S.A., together with its subsidiaries, develops, produces, markets, distributes, and maintains a portfolio of minimally invasive medical devices for the treatment of urological diseases in Asia, France, the United States, and internationally. It operates in three segments: High Intensity Focused Ultrasound (HIFU), Extracorporeal ShockWave Lithotripsy (ESWL), and Distribution Services (DIST). The HIFU segment develops, manufactures, and markets medical devices based on HIFU technology for the minimally invasive treatment of urological and other clinical indications. This segment also offers Ablatherm, an ultrasound guided robotic HIFU device for the treatment of organ-confined prostate cancer; Ablatherm Fusion that incorporates the company's proprietary fusion software, which merges MRI and ultrasound images; and the Focal One, a HIFU robotic device dedicated to the focal therapy of prostate cancer, as well as disposables, and leasing and treatment related services; and maintenance services. The ESWL division manufactures, markets, and services lithotripter for the treatment of urinary tract stones by means of ESWL technology; and offers Sonolith i-move, an extracorporeal shockwave lithotripter to small and mid-size hospitals, as well as sells disposable parts for lithotripters and electrodes. The Distribution division markets, distributes, and services lasers, micro-ultrasound systems, and other medical products from third parties, as well as leases devices; sells disposables and spare parts; and offers maintenance services. The company markets and sells its products through its direct marketing, sales organization, and service platform, as well as through third-party distributors and agents. Its customers include hospitals, urology clinics, and research institutions. The company was incorporated in 1979 and is headquartered in Lyon, France.